Ribociclib-induced hepatotoxicity
| dc.contributor.author | Muhiddin, Er Muhammed | |
| dc.contributor.author | Araz, Murat | |
| dc.contributor.author | Hendem, Engin | |
| dc.contributor.author | Eryilmaz, Melek Karakurt | |
| dc.contributor.author | Artac, Mehmet | |
| dc.date.accessioned | 2024-02-23T14:27:03Z | |
| dc.date.available | 2024-02-23T14:27:03Z | |
| dc.date.issued | 2023 | |
| dc.department | NEÜ | en_US |
| dc.description.abstract | Introduction Cyclin-dependent kinase (CDK) 4/6 inhibitors have shown a different adverse effect. In this case, persistent grade 3 hepatoxicity was observed after ribociclib. Therefore, ribociclib therapy was stopped, and then palbociclib was introduced. Transaminase levels returned to normal by switching to palbociclib therapy. Case report 71-year-old postmenopausal female patient with luminal subtypes of metastatic breast cancer treated with ribociclib. Management & outcome Grade 3 hepatotoxicity secondary to ribociclib developed. She was successfully treated with palbociclib 125 mg. Discussion In our case, palbociclib was started with a full dose, to increase treatment success. Starting with a 125 mg dose was not cause any toxicity. Nevertheless, laboratory follow-up is required in terms of neutropenia and increased transaminases. | en_US |
| dc.identifier.doi | 10.1177/10781552231154009 | |
| dc.identifier.endpage | 1277 | en_US |
| dc.identifier.issn | 1078-1552 | |
| dc.identifier.issn | 1477-092X | |
| dc.identifier.issue | 5 | en_US |
| dc.identifier.pmid | 36762416 | en_US |
| dc.identifier.scopus | 2-s2.0-85148520987 | en_US |
| dc.identifier.scopusquality | Q3 | en_US |
| dc.identifier.startpage | 1275 | en_US |
| dc.identifier.uri | https://doi.org/10.1177/10781552231154009 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.12452/14433 | |
| dc.identifier.volume | 29 | en_US |
| dc.identifier.wos | WOS:000931784000001 | en_US |
| dc.indekslendigikaynak | Web of Science | en_US |
| dc.indekslendigikaynak | Scopus | en_US |
| dc.indekslendigikaynak | PubMed | en_US |
| dc.language.iso | en | en_US |
| dc.publisher | Sage Publications Ltd | en_US |
| dc.relation.ispartof | Journal Of Oncology Pharmacy Practice | en_US |
| dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| dc.rights | info:eu-repo/semantics/closedAccess | en_US |
| dc.subject | Ribociclib | en_US |
| dc.subject | Metastatic Breast Cancer | en_US |
| dc.subject | Hepatotoxicity | en_US |
| dc.title | Ribociclib-induced hepatotoxicity | en_US |
| dc.type | Article | en_US |
